Host IL28B genotype is known to be a strong predictor of response to interferon-based therapy [26, 27], while patients with variants in the ITPA gene are known to be protected against ribavirin-induced anemia during treatment with peginterferon-containing regimens [12]. The gene discussed is ITPA; the disease is anemia (phenotype).